看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。, d4 J! u& n, P! K
" P7 G6 E/ D7 d
; W! \' \: q) d3 W& \5 d- Q
Currently available feasibility data for possible combination strategies.
! @6 v6 T' |; q9 g+ L& ]% Q————————————————————————————————
! d5 t* b: h1 `Combination Feasibility according to preliminary data
7 O& C1 O& W& x5 z6 K——————————————————————————————————; m# Y* `8 P8 o) `
Bevacizumab + sorafenib Yes, reduced dose " Q8 O; i! V! a% @+ t
Bevacizumab + sunitinib† No 0 l# y' a$ v6 N8 }* [
Bevacizumab + temsirolimus Yes
- o- D: {0 Y- w8 OBevacizumab + everolimus Yes
( N' Q) k. _1 h( BSorafenib + sunitinib ?
# {! N% I5 i o7 ]Sorafenib + temsirolimus Yes, reduced dose + N L- x. O* ?7 C! O# A
Sorafenib + everolimus Yes, reduced dose ) K/ ?: B }+ w1 v6 |4 W* g8 d
Sunitinib + temsirolimus† No ( h" U% A" X) P9 p1 `# _9 {
Sunitinib + everolimus ? " m7 f, u1 P j3 y
Temsirolimus + everolimus ? * @ [( o. [/ M' \# B+ R
————————————————————3 K# t$ @3 U$ \7 L
†Led to US FDA warning.
, _3 D: u+ p; R4 E* L8 l( f7 K?: As yet unattempted combination.7 @; S) l% h' f0 |# d( R" e, k" M
|